biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > I sure like this Jon

<< Previous

Bullboard Posts

Next >>

Comment by zwerp2000on Oct 05, 2023 9:40am

197 Views

Post# 35670787

RE:RE:RE:RE:RE:RE:RE:RE:I sure like this Jon

and you have no proof that xb3 does work. i look at the facts though. company is broke. company is going bye-bye. company can't find anyone to save them. multiple companies looked at their technology and passed. if there was any value, someone could have picked them up for nothing but no one did. based on that, i would say my view is probably the correct view

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023